1: Kovács SA, Fekete JT, Győrffy B. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacol Sin. 2023 Apr 13. doi: 10.1038/s41401-023-01079-6. Epub ahead of print. PMID: 37055532.
2: Bell HN, Huber AK, Singhal R, Korimerla N, Rebernick RJ, Kumar R, El-Derany MO, Sajjakulnukit P, Das NK, Kerk SA, Solanki S, James JG, Kim D, Zhang L, Chen B, Mehra R, Frankel TL, Győrffy B, Fearon ER, Pasca di Magliano M, Gonzalez FJ, Banerjee R, Wahl DR, Lyssiotis CA, Green M, Shah YM. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab. 2023 Jan 3;35(1):134-149.e6. doi: 10.1016/j.cmet.2022.11.013. Epub 2022 Dec 16. PMID: 36528023; PMCID: PMC9841369.
3: Győrffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023 Mar 1. doi: 10.1007/s11357-023-00742-4. Epub ahead of print. PMID: 36856946.
4: Fekete JT, Győrffy B. New Transcriptomic Biomarkers of 5-Fluorouracil Resistance. Int J Mol Sci. 2023 Jan 12;24(2):1508. doi: 10.3390/ijms24021508. PMID: 36675023; PMCID: PMC9867124.
5: Győrffy B, Weltz B, Szabó I. Supporting grant reviewers through the scientometric ranking of applicants. PLoS One. 2023 Jan 20;18(1):e0280480. doi: 10.1371/journal.pone.0280480. PMID: 36662799; PMCID: PMC9858403.
6: Varadi M, Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O, Szendroi A, Ablat J, Black PC, Keresztes D, Csizmarik A, Olah C, Gaisa NT, Kiss A, Timar J, Toth E, Csernak E, Gerstner A, Mittal V, Karkampouna S, Kruithof de Julio M, Gyorffy B, Bedics G, Rink M, Fisch M, Nyirady P, Szarvas T. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas. Cancer Med. 2023 Jan 20. doi: 10.1002/cam4.5639. Epub ahead of print. PMID: 36670542.
7: Kothalawala WJ, Győrffy B. Transcriptomic and Cellular Content Analysis of Colorectal Cancer by Combining Multiple Independent Cohorts. Clin Transl Gastroenterol. 2023 Feb 1;14(2):e00517. doi: 10.14309/ctg.0000000000000517. PMID: 35858620; PMCID: PMC9945259.
8: Morafraile EC, Saiz-Ladera C, Nieto-Jiménez C, Győrffy B, Nagy A, Velasco G, Pérez-Segura P, Ocaña A. Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers. Curr Oncol. 2023 Feb 21;30(3):2569-2581. doi: 10.3390/curroncol30030196. PMID: 36975409; PMCID: PMC10047091.
9: Bartha Á, Darula Z, Munkácsy G, Klement É, Nyirády P, Győrffy B. Proteotranscriptomic Discrimination of Tumor and Normal Tissues in Renal Cell Carcinoma. Int J Mol Sci. 2023 Feb 24;24(5):4488. doi: 10.3390/ijms24054488. PMID: 36901940; PMCID: PMC10003397.
10: Olah C, Reis H, Hoffmann MJ, Mairinger F, Ting S, Hadaschik B, Krafft U, Grünwald V, Nyirady P, Varadi M, Győrffy B, Kiss A, Szekely E, Sjödahl G, Szarvas T. Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer. Cancer Med. 2023 Mar;12(5):5222-5232. doi: 10.1002/cam4.5324. Epub 2022 Oct 7. PMID: 36204983; PMCID: PMC10028049.
11: Barone I, Gelsomino L, Accattatis FM, Giordano F, Gyorffy B, Panza S, Giuliano M, Veneziani BM, Arpino G, De Angelis C, De Placido P, Bonofiglio D, Andò S, Giordano C, Catalano S. Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a. J Transl Med. 2023 Mar 31;21(1):232. doi: 10.1186/s12967-023-04075-w. PMID: 37004031; PMCID: PMC10064709.
12: Pipek O, Vizkeleti L, Doma V, Alpár D, Bödör C, Kárpáti S, Timar J. The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries. Cancers (Basel). 2023 Mar 10;15(6):1712. doi: 10.3390/cancers15061712. PMID: 36980598; PMCID: PMC10046270.
13: Munkácsy G, Santarpia L, Győrffy B. Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. Int J Mol Sci. 2023 Apr 8;24(8):6945. doi: 10.3390/ijms24086945. PMID: 37108109; PMCID: PMC10138520.
14: Al Bakir M, Huebner A, Martínez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S, Laycock J, Johnson D, Rowan A, Razaq M, Akther M, Naceur-Lombardelli C, Prymas P, Toncheva A, Hessey S, Dietzen M, Colliver E, Frankell AM, Bunkum A, Lim EL, Karasaki T, Abbosh C, Hiley CT, Hill MS, Cook DE, Wilson GA, Salgado R, Nye E, Stone RK, Fennell DA, Price G, Kerr KM, Naidu B, Middleton G, Summers Y, Lindsay CR, Blackhall FH, Cave J, Blyth KG, Nair A, Ahmed A, Taylor MN, Procter AJ, Falzon M, Lawrence D, Navani N, Thakrar RM, Janes SM, Papadatos-Pastos D, Forster MD, Lee SM, Ahmad T, Quezada SA, Peggs KS, Van Loo P, Dive C, Hackshaw A, Birkbak NJ, Zaccaria S; TRACERx Consortium; Jamal-Hanjani M, McGranahan N, Swanton C. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 12. PMID: 37046095; PMCID: PMC10115651.
15: Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, Kidd AC, Frankell AM, Watkins TBK, Martínez-Ruiz C, Puttick C, Black JRM, Huebner A, Bakir MA, Sokač M, Collins S, Veeriah S, Magno N, Naceur-Lombardelli C, Prymas P, Toncheva A, Ward S, Jayanth N, Salgado R, Bridge CP, Christiani DC, Mak RH, Bay C, Rosenthal M, Sattar N, Welsh P, Liu Y, Perrimon N, Popuri K, Beg MF, McGranahan N, Hackshaw A, Breen DM, O’Rahilly S, Birkbak NJ, Aerts HJWL; TRACERx Consortium; Jamal-Hanjani M, Swanton C. Body composition and lung cancer-associated cachexia in TRACERx. Nat Med. 2023 Apr;29(4):846-858. doi:10.1038/s41591-023-02232-8. Epub 2023 Apr 12. PMID: 37045997; PMCID: PMC7614477.
16: Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A, Hill MS, Grigoriadis K, Moore DA, Black JRM, Liu WK, Thol K, Pich O, Watkins TBK, Naceur-Lombardelli C, Cook DE, Salgado R, Wilson GA, Bailey C, Angelova M, Bentham R, Martínez-Ruiz C, Abbosh C, Nicholson AG, Le Quesne J, Biswas D, Rosenthal R, Puttick C, Hessey S, Lee C, Prymas P, Toncheva A, Smith J, Xing W, Nicod J, Price G, Kerr KM, Naidu B, Middleton G, Blyth KG, Fennell DA, Forster MD, Lee SM, Falzon M, Hewish M, Shackcloth MJ, Lim E, Benafif S, Russell P, Boleti E, Krebs MG, Lester JF, Papadatos-Pastos D, Ahmad T, Thakrar RM, Lawrence D, Navani N, Janes SM, Dive C, Blackhall FH, Summers Y, Cave J, Marafioti T, Herrero J, Quezada SA, Peggs KS, Schwarz RF, Van Loo P, Miedema DM, Birkbak NJ, Hiley CT, Hackshaw A, Zaccaria S; TRACERx Consortium; Jamal-Hanjani M, McGranahan N, Swanton C. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-533. doi: 10.1038/s41586-023-05783-5. Epub 2023 Apr 12. PMID: 37046096; PMCID: PMC10115649.
17: Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L’Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium; Birkbak NJ, McGranahan N, Swanton C.Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA Nature. 2023 Apr;616(7957):553-562. doi: 10.1038/s41586-023-05776-4. Epub 2023 Apr 13. PMID: 37055640.
18: Lazar J, Antal-Szalmas P, Kurucz I, Ferenczi A, Jozsi M, Tornyi I, Muller M, Fekete JT, Lamont J, FitzGerald P, Gall-Debreceni A, Kadas J, Vida A, Tardieu N, Kieffer Y, Jullien A, Guergova-Kuras M, Hempel W, Kovacs A, Kardos T, Bittner N, Csanky E, Szilasi M, Losonczy G, Szondy K, Galffy G, Csada E, Szalontai K, Somfay A, Malka D, Cottu P, Bogos K, Takacs L. Large scale plasma proteome epitome profiling is an efficient tool for the discovery of cancer biomarkers. Mol Cell Proteomics. 2023 May 19:100580. doi: 10.1016/j.mcpro.2023.100580. Epub ahead of print. PMID: 37211046.
19: Jankó L, Tóth E, Laczik M, Rauch B, Janka E, Bálint BL, Bai P. PARP2 poly(ADP-ribosyl)ates nuclear factor erythroid 2-related factor 2 (NRF2) affecting NRF2 subcellular localization. Sci Rep. 2023 May 15;13(1):7869. doi: 10.1038/s41598-023-35076-w. PMID: 37188809; PMCID: PMC10185692.
20: Karasaki T, Moore DA, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA, Watkins TBK, Grigoriadis K, Huebner A, Hill MS, Frankell AM, Abbosh C, Puttick C, Zhai H, Gimeno-Valiente F, Saghafinia S, Kanu N, Dietzen M, Pich O, Lim EL, Martínez-Ruiz C, Black JRM, Biswas D, Campbell BB, Lee C, Colliver E, Enfield KSS, Hessey S, Hiley CT, Zaccaria S, Litchfield K, Birkbak NJ, Cadieux EL, Demeulemeester J, Van Loo P, Adusumilli PS, Tan KS, Cheema W, Sanchez-Vega F, Jones DR, Rekhtman N, Travis WD, Hackshaw A, Marafioti T, Salgado R, Le Quesne J, Nicholson AG; TRACERx Consortium; McGranahan N, Swanton C, Jamal-Hanjani M. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nat Med. 2023 Apr;29(4):833-845. doi:10.1038/s41591-023-02230-w. Epub 2023 Apr 12. PMID: 37045996; PMCID: PMC7614478.
21: Woldmar N, Schwendenwein A, Kuras M, Szeitz B, Boettiger K, Tisza A, László V, Reiniger L, Bagó AG, Szállási Z, Moldvay J, Szász AM, Malm J, Horvatovich P, Pizzatti L, Domont GB, Rényi-Vámos F, Hoetzenecker K, Hoda MA, Marko-Varga G, Schelch K, Megyesfalvi Z, Rezeli M, Döme B. Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases. ESMO Open. 2023 Feb;8(1):100741. doi: 10.1016/j.esmoop.2022.100741. Epub 2022 Dec 16. PMID: 36527824; PMCID: PMC10024110.
22: Posta M, Győrffy B. Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors. Clin Transl Sci. 2023 Jun 1. doi: 10.1111/cts.13563. Epub ahead of print. PMID: 37260110.
23: Naimo GD, Forestiero M, Paolì A, Malivindi R, Gelsomino L, Győrffy B,Leonetti AE, Giordano F, Panza S, Conforti FL, Ruffo P, Panno ML, Mauro L, Andò S. ERα/LKB1 complex upregulates E-cadherin expression and stimulates breast cancer growth and progression upon adiponectin exposure. Int J Cancer. 2023 Jun 16. doi: 10.1002/ijc.34626. Epub ahead of print. PMID: 37323038.
24: Szepesi Kovács D, Chiovini B, Müller D, Tóth EZ, Fülöp A, Ábrányi-Balogh P, Wittner L, Várady G, Farkas Ö, Turczel G, Katona G, Győrffy B, Keserű GM, Mucsi Z, Rózsa BJ, Kovács E. Synthesis and Application of Two-Photon Active Fluorescent Rhodol Dyes for Antibody Conjugation and In Vitro Cell Imaging. ACS Omega. 2023 Jun 14;8(25):22836-22843. doi: 10.1021/acsomega.3c01796. PMID: 37396252; PMCID: PMC10308389.
25: Chetverina D, Vorobyeva NE, Gyorffy B, Shtil AA, Erokhin M. Analyses of Genes Critical to Tumor Survival Reveal Potential ‘Supertargets’: Focus on Transcription. Cancers (Basel). 2023 Jun 3;15(11):3042. doi: 10.3390/cancers15113042. PMID: 37297004; PMCID: PMC10252933.
26: Gyulai M, Megyesfalvi Z, Reiniger L, Harko T, Ferencz B, Karsko L, Agocs L, Fillinger J, Dome B, Szallasi Z, Moldvay J. PD-1 and PD-L1 expression in rare lung tumors. Pathol Oncol Res. 2023 May 18;29:1611164. doi: 10.3389/pore.2023.1611164. PMID: 37274772; PMCID: PMC10232779.
27: Matsumoto S, Tsunashima R, Kitano S, Watanabe A, Kato C, Morita M, Sakaguchi K, Győrffy B, Naoi Y. Multi-gene assay 95- and 155-gene classifiers for prognosis prediction and chemotherapy omission in lymphnode positive luminal-type breast cancer. Cancer Treat Res Commun. 2023 May 18;36:100711. doi: 10.1016/j.ctarc.2023.100711. Epub ahead of print. PMID: 37245351.
28: Fu X, Pereira R, Liu CC, De Angelis C, Shea MJ, Nanda S, Qin L, Mitchell T, Cataldo ML, Veeraraghavan J, Sethunath V, Giuliano M, Gutierrez C, Győrffy B, Trivedi MV, Cohen O, Wagle N, Nardone A, Jeselsohn R, Rimawi MF, Osborne CK, Schiff R. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Rep. 2023 Jul 18;42(8):112821. doi: 10.1016/j.celrep.2023.112821. Epub ahead of print. PMID: 37467106.
29: Mangó K, Fekete F, Kiss ÁF, Erdős R, Fekete JT, Bűdi T, Bruckner E, Garami M, Micsik T, Monostory K. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma. Sci Rep. 2023 Jul 21;13(1):11770. doi: 10.1038/s41598-023-38983-0. PMID: 37479763; PMCID: PMC10361978.
30: Roche ME, Ko YH, Domingo-Vidal M, Lin Z, Whitaker-Menezes D, Birbe RC, Tuluc M, Győrffy B, Caro J, Philp NJ, Bartrons R, Martinez-Outschoorn U. TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer. Int J Cancer. 2023 Jul 27. doi: 10.1002/ijc.34660. Epub ahead of print. PMID: 37497753.
31: Herold M, Szasz AM, Szentmartoni G, Martinek E, Madar-Dank V, Barna AJ, Mohacsi R, Somogyi A, Dank M, Herold Z. Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes. Sci Rep. 2023 Aug 10;13(1):12985. doi: 10.1038/s41598-023-40216-3. PMID: 37563292; PMCID: PMC10415401.
32: DeAngelo SL, Győrffy B, Koutmos M, Shah YM. Selenoproteins and tRNA-Sec: regulators of cancer redox homeostasis. Trends Cancer. 2023 Sep 14:S2405-8033(23)00163-2. doi: 10.1016/j.trecan.2023.08.003. Epub ahead of print. PMID: 37716885.
33: Gyulai M, Harko T, Fabian K, Karsko L, Agocs L, Szigeti B, Fillinger J, Szallasi Z, Pipek O, Moldvay J. Claudin expression in pulmonary adenoid cystic carcinoma and mucoepidermoid carcinoma. Pathol Oncol Res. 2023 Aug 9;29:1611328. doi: 10.3389/pore.2023.1611328. PMID: 37621953; PMCID: PMC10444951.
34: Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, Cheong TC, Leonardi G, Karaca-Atabay E, Campisi M, Poggio T, Menotti M, Ambrogio C, Longo DL, Klaeger S, Keshishian H, Sztupinszki ZM, Szallasi Z, Keskin DB, Duke-Cohan JS, Reinhold B, Carr SA, Wu CJ, Moynihan KD, Irvine DJ, Barbie DA, Reinherz EL, Voena C, Awad MM, Blasco RB, Chiarle R. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer. 2023 Jul;4(7):1016-1035. doi: 10.1038/s43018-023-00591-2. Epub 2023 Jul 10. PMID: 37430060.
35: Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M, Young G, Molina-Arcas M, de Carné Trécesson S, Anastasiou P, Fendler A, Au L, Shepherd STC, Martínez-Ruiz C, Puttick C, Black JRM, Watkins TBK, Kim H, Shim S, Faulkner N, Attig J, Veeriah S, Magno N, Ward S, Frankell AM, Al Bakir M, Lim EL, Hill MS, Wilson GA, Cook DE, Birkbak NJ, Behrens A, Yousaf N, Popat S, Hackshaw A; TRACERx Consortium; CAPTURE Consortium; Hiley CT, Litchfield K, McGranahan N, Jamal-Hanjani M, Larkin J, Lee SH, Turajlic S, Swanton C, Downward J, Kassiotis G. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023 Apr; 616(7957):563-573. doi: 10.1038/s41586-023-05771-9. Epub 2023 Apr 12. PMID: 37046094; PMCID: PMC10115647.
36: Qin Y, Ashrafizadeh M, Mongiardini V, Grimaldi B, Crea F, Rietdorf K, Győrffy B, Klionsky DJ, Ren J, Zhang W, Zhang X. Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence. Cancer Lett. 2023 Aug 28;570:216307. doi: 10.1016/j.canlet.2023.216307. Epub 2023 Jul 12. PMID: 37451426.
37: Szeitz B, Glasz T, Herold Z, Tóth G, Balbisi M, Fillinger J, Horváth S, Mohácsi R, Kwon HJ, Moldvay J, Turiák L, Szász AM. Spatially Resolved Proteomic and Transcriptomic Profiling of Anaplastic Lymphoma Kinase-Rearranged Pulmonary Adenocarcinomas Reveals Key Players in Inter- and Intratumoral Heterogeneity. Int J Mol Sci. 2023 Jul 12;24(14):11369. doi: 10.3390/ijms241411369. PMID: 37511126; PMCID: PMC10380216.
38: Szluka P, Csajbók E, Győrffy B. Relationship between bibliometric indicators and university ranking positions. Sci Rep. 2023 Aug 30;13(1):14193. doi: 10.1038/s41598-023-35306-1. PMID: 37648684; PMCID: PMC10468493.
39: Vízkeleti L, Spisák S. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers. Cells. 2023 Jun 29;12(13):1745. doi: 10.3390/cells12131745. PMID: 37443779; PMCID: PMC10341379.
40: Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Győrffy B, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Biasi O, Seitz RS, Valagussa P, Viale G, Gianni L, Bianchini G, Ali HR. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6. PMID:37674077; PMCID: PMC10533410.
41: Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C, Toncheva A, Prymas P, Rowan A, Ward S, Cubitt L, Athanasopoulou F, Pich O, Karasaki T, Moore DA, Salgado R, Colliver E, Castignani C, Dietzen M, Huebner A, Al Bakir M, Tanić M, Watkins TBK, Lim EL, Al-Rashed AM, Lang D, Clements J, Cook DE, Rosenthal R,Wilson GA, Frankell AM, de Carné Trécesson S, East P, Kanu N, Litchfield K, Birkbak NJ, Hackshaw A, Beck S, Van Loo P, Jamal-Hanjani M; TRACERx Consortium; Swanton C, McGranahan N. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023 Apr;616(7957):543-552. doi: 10.1038/s41586-023-05706-4. Epub 2023 Apr 12. PMID: 37046093; PMCID: PMC10115639.
42: Menyhárt O, Fekete TJ, Győrffy B. A gyulladáshoz köthető jelátviteli utak fokozott aktivitása antraciklin-paklitaxel rezisztens emlőkarcinómákban [Increased activity of inflammation-related signaling pathways in anthracycline-paclitaxel resistant breast carcinomas]. Magy Onkol. 2023 Sep 28;67(3):203-212. Hungarian. Epub 2023 Sep 7. PMID: 37768118.
43: Győrffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024 Feb;181(3):362-374. doi: 10.1111/bph.16257. Epub 2023 Nov 23. PMID: 37783508.
44: Sánchez-Tilló E, Pedrosa L, Vila I, Chen Y, Győrffy B, Sánchez-Moral L, Siles L, Lozano JJ, Esteve-Codina A, Darling DS, Cuatrecasas M, Castells A, Maurel J, Postigo A. The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas. JCI Insight. 2023 Oct 23;8(20):e164629. doi: 10.1172/jci.insight.164629. PMID: 37870961.
45: Paniagua-Herranz L, Doger B, Díaz-Tejeiro C, Sanvicente A, Nieto-Jiménez C, Moreno V, Pérez Segura P, Gyorffy B, Calvo E, Ocana A. Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities. Cancers (Basel). 2023 Jun 20;15(12):3250. doi: 10.3390/cancers15123250. PMID: 37370859; PMCID: PMC10297015.
46: Resál T, Bacsur P, Horváth M, Szántó K, Rutka M, Bálint A, Fábián A, Bor R, Szepes Z, Fekete J, Farkas K, Miheller P, Molnár T. Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination. Therap Adv Gastroenterol. 2023 Jul 14;16:17562848231183529. doi: 10.1177/17562848231183529. PMID: 37461738; PMCID: PMC10350576.
47: Prekovic S, Chalkiadakis T, Roest M, Roden D, Lutz C, Schuurman K, Opdam M, Hoekman L, Abbott N, Tesselaar T, Wajahat M, Dwyer AR, Mayayo-Peralta I, Gomez G, Altelaar M, Beijersbergen R, Győrffy B, Young L, Linn S, Jonkers J, Tilley W, Hickey T, Vareslija D, Swarbrick A, Zwart W. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity. EMBO Mol Med. 2023 Oct 30:e17737. doi: 10.15252/emmm.202317737. Epub ahead of print. PMID: 37902007.
48: Licata L, Barreca M, Galbardi B, Dugo M, Viale G, Győrffy B, Karn T, Pusztai L, Gianni L, Callari M, Bianchini G. Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy. Br J Cancer. 2023 Nov 7. doi: 10.1038/s41416-023-02477-7. Epub ahead of print. PMID: 37935787.
49: Sgarzi M, Mazzeschi M, Santi S, Montacci E, Panciera T, Ferlizza E, Girone C, Morselli A, Gelfo V, Kuhre RS, Cavallo C, Valente S, Pasquinelli G, Győrffy B, D’Uva G, Romaniello D, Lauriola M. Aberrant MET activation impairs perinuclear actin cap organization with YAP1 cytosolic relocation. Commun Biol. 2023 Oct 14;6(1):1044. doi: 10.1038/s42003-023-05411-y. PMID: 37838732; PMCID: PMC10576810.
50: Zhou Y, Börcsök J, Adib E, Kamran SC, Neil AJ, Stawiski K, Freeman D, Stormoen DR, Sztupinszki Z, Samant A, Nassar A, Bekele RT, Hanlon T, Valentine H, Epstein I, Sharma B, Felt K, Abbosh P, Wu CL, Efstathiou JA, Miyamoto DT, Anderson W, Szallasi Z, Mouw KW. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Sci Adv. 2023 Nov 24;9(47):eadg2263. doi: 10.1126/sciadv.adg2263. Epub 2023 Nov 22. PMID: 37992168; PMCID: PMC10664985.
51: Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023 Dec 4. doi: 10.1038/s41591-023-02735-4. Epub ahead of print. Erratum for: Nat Med. 2023 Nov;29(11):2737-2741. PMID: 38049623.
52: Szepesi Kovács D, Kontra B, Chiovini B, Müller D, Tóth EZ, Ábrányi-Balogh P, Wittner L, Várady G, Turczel G, Farkas Ö, Owen MC, Katona G, Győrffy B, Keserű GM, Mucsi Z, Rózsa BJ, Kovács E. Effective synthesis, development and application of a highly fluorescent cyanine dye for antibody conjugation and microscopy imaging. Org Biomol Chem. 2023 Nov 15;21(44):8829-8836. doi: 10.1039/d3ob01471a. PMID: 37917021.
53: Wang Z, Zhang N, Zhang M, Jiang Y, Ng AS, Bridges E, Zhang W, Zeng X, Luo Q, Liang J, Győrffy B, Hublitz P, Liang Z, Fischer R, Kerr D, Harris AL, Cai S. GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner. Cancer Res. 2023 Oct 13;83(20):3400-3413. doi: 10.1158/0008-5472.CAN-22-3471. PMID: 37463466.
54: Jambrich MA, Tusnady GE, Dobson L. How AlphaFold2 shaped the structural coverage of the human transmembrane proteome. Sci Rep. 2023 Nov 20;13(1):20283. doi: 10.1038/s41598-023-47204-7. PMID: 37985809; PMCID: PMC10662385.1: Tusnády GE, Zeke A, Kálmán ZE, Fatoux M, Ricard-Blum S, Gibson TJ, Dobson L. LeishMANIAdb: a comparative resource for Leishmania proteins. Database (Oxford). 2023 Oct 31;2023:baad074. doi: 10.1093/database/baad074. PMID: 37935582; PMCID: PMC10627299.
55: Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, Kuan FC, Marongiu F, Evans EJ Jr, Moore DA, Rodrigues FS, Pich O, Bakker B, Cha H, Myers R, van Maldegem F, Boumelha J, Veeriah S, Rowan A, Naceur-Lombardelli C, Karasaki T, Sivakumar M, De S, Caswell DR, Nagano A, Black JRM, Martínez-Ruiz C, Ryu MH, Huff RD, Li S, Favé MJ, Magness A, Suárez-Bonnet A, Priestnall SL, Lüchtenborg M, Lavelle K, Pethick J, Hardy S, McRonald FE, Lin MH, Troccoli CI, Ghosh M, Miller YE, Merrick DT, Keith RL, Al Bakir M, Bailey C, Hill MS, Saal LH, Chen Y, George AM, Abbosh C, Kanu N, Lee SH, McGranahan N, Berg CD, Sasieni P, Houlston R, Turnbull C, Lam S, Awadalla P, Grönroos E, Downward J, Jacks T, Carlsten C, Malanchi I, Hackshaw A, Litchfield K; TRACERx Consortium; DeGregori J, Jamal- Hanjani M, Swanton C. Lung adenocarcinoma promotion by air pollutants. Nature. 2023 Apr;616(7955):159-167. doi: 10.1038/s41586-023-05874-3. Epub 2023 Apr 5. PMID: 37020004; PMCID: PMC7614604.
56: Giordano C, Accattatis FM, Gelsomino L, Del Console P, Győrffy B, Giuliano M, Veneziani BM, Arpino G, De Angelis C, De Placido P, Pietroluongo E, Zinno F, Bonofiglio D, Andò S, Barone I, Catalano S. miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer. Int J Mol Sci. 2023 Oct 28;24(21):15695. doi: 10.3390/ijms242115695. PMID: 37958677; PMCID: PMC10649351.
57: Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus GT, Börcsök J, Sztupinszki Z, Hanlon T, Diossy M, Vizkeleti L, Stormoen DR, Csabai I, Pappot H, Vijai J, Offit K, Ried T, Sethi N, Mouw KW, Spisak S, Pathania S, Szallasi Z. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. bioRxiv [Preprint]. 2023 Feb 7:2023.02.07.527498. doi: 10.1101/2023.02.07.527498. Update in: Sci Rep. 2023 Nov 23;13(1):20567. PMID: 36798363; PMCID: PMC9934582.
58: Dobson L, Gerdán C, Tusnády S, Szekeres L, Kuffa K, Langó T, Zeke A, Tusnády GE. UniTmp: unified resources for transmembrane proteins. Nucleic Acids Res. 2023 Oct 23:gkad897. doi: 10.1093/nar/gkad897. Epub ahead of print. PMID: 37870462.
59: Bosi C, Bartha Á, Galbardi B, Notini G, Naldini MM, Licata L, Viale G, Mariani M, Pistilli B, Ali HR, André F, Piras M, Callari M, Barreca M, Locatelli A, Viganò L, Criscitiello C, Pusztai L, Curigliano G, Győrffy B, Dugo M, Bianchini G. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. Eur J Cancer. 2023 Dec;195:113379. doi: 10.1016/j.ejca.2023.113379. Epub 2023 Oct 11. PMID: 37913680.
60: Menyhárt O, Győrffy B. Dietary approaches for exploiting metabolic vulnerabilities in cancer. Biochim Biophys Acta Rev Cancer. 2023 Dec 28;1879(2):189062. doi: 10.1016/j.bbcan.2023.189062. Epub ahead of print. PMID: 38158024.